IN-CUMMINS-INC.
22.9.2022 09:57:25 CEST | Business Wire | Press release
Cummins Inc. (NYSE: CMI) is showcasing its platform of zero-emissions technologies this week at the IAA Transportation show, the world's largest mobility show, in Hannover, Germany. A range of new Cummins technologies and the recently acquired Meritor ePowertrain technologies are available publicly together for the first time. With over a century of experience as a global power leader, Cummins is solidifying its commitment to providing comprehensive zero-emissions technology on a global scale.
"Cummins has deep application expertise, and we are uniquely positioned to deliver solutions that truly fit the needs of commercial applications," said Amy Davis, Vice President and President of New Power at Cummins. "Realizing a net-zero future will require a range of technologies. Our extensive zero-emissions portfolio is how we will meet varied customer demands across the hardest-to-abate industries and make the energy transition possible."
One key zero-emissions product Cummins revealed at IAA is its fourth-generation hydrogen fuel cell engine. Designed to meet the duty-cycle, performance and packaging requirements of medium- and heavy-duty trucks and buses, the fuel cell technology is available in 135 kW single and 270 kW dual modules.
Scania in Europe and Daimler Trucks North America have each announced collaborations with Cummins to develop and integrate these next-generation fuel cell engines into demonstrator vehicles. The systems use fourth-generation variable pressure technology to provide higher power density, power nodes and operating temperatures for easier system integration into vehicles. They also have strong operating cycle efficiency and durability for a lower total cost of ownership.
“We know our customers have diverse needs and complicated duty cycles to support, which is why we focus on continued innovation and improvement,” said Amy Adams, Vice President of Fuel Cell and Hydrogen Technologies at Cummins. “We’re developing hydrogen fuel cell technology that demonstrates the capacity and flexibility required to meet or exceed the power needs for on-highway commercial vehicles – proving hydrogen as a viable solution to decarbonize the economy.”
Attendees at IAA will also get the first glimpse of a drivetrain assembled with a newly introduced Cummins lithium iron phosphate (LFP) battery pack, Meritor’s 17xe ePowertrain and Meritor’s Power Control and Accessory System (PCAS). Cummins recently added the ePowertain and PCAS solutions to its portfolio through its acquisition of Meritor. The ePowertrain leverages market-leading technologies in the axle, motor and inverter, delivering performance, efficiency and packaging advantages at a competitive cost. Additionally, the PCAS provides power where needed and control of necessary sub-systems while reducing packaging size and simplifying integration.
Cummins is adding an LFP battery to its line of lithium-ion battery products to expand support of electrified commercial vehicle applications. The LFP solution gives customers access to faster charging and longer-life batteries, targeting the medium-duty truck and school bus markets. By using a multi-chemistry strategy, Cummins is positioned to expand its manufacturing capacity further and diversify its supply chain, providing customers with more cost-effective electrification solutions.
"We are giving customers options to enable them to adapt to a zero-emissions future faster," said Brian Wilson, General Manager of Electrified Components at Cummins. "With the recent acquisition of Meritor and our new multi-chemistry approach, we will be able to tailor our solutions and offer a one-stop-shop for customers' powertrain needs."
Cummins' portfolio includes four batteries, each of which targets a different duty cycle and use case and complement each other. In addition to the LFP option, this includes three nickel manganese cobalt (NMC) batteries – the BP95E, BP74E and BP30E. The BP95E is Cummins’ next-generation solution that prioritizes greater energy density in applications for customers who need more weight-sensitive solutions or have longer ranges. The BP30E is ideal for meeting limited-space applications and rugged demands, and the BP74E is the foundation for Cummins’ BEV innovation and progress.
Download Cummins product photos.
About Cummins Inc.
Cummins Inc., a global power leader, is a corporation of complementary business segments that design, manufacture, distribute and service a broad portfolio of power solutions. The company’s products range from diesel, natural gas, electric and hybrid powertrains, and powertrain-related components including filtration, aftertreatment, turbochargers, fuel systems, controls systems, air handling systems, automated transmissions, electric power generation systems, batteries, electrified power systems, hydrogen generation and fuel cell products. Headquartered in Columbus, Indiana (U.S.), since its founding in 1919, Cummins employs approximately 59,900 people committed to powering a more prosperous world through three global corporate responsibility priorities critical to healthy communities: education, environment, and equality of opportunity. Cummins serves its customers online, through a network of company-owned and independent distributor locations, and through thousands of dealer locations worldwide and earned about $2.1 billion on sales of $24.0 billion in 2021. See how Cummins is powering a world that is always on by accessing news releases and more information at https://www.cummins.com/always-on.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005980/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
